A Study of Venetoclax and Alvocidib in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Trial Status: Closed to Accrual
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R / R) acute myeloid leukemia (AML).
- Must have adequate coagulation, hematology, kidney, and liver function, per protocol.
- Diagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML)
- Meet the following disease activity criteria:
- an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and
- an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
- - If male participant is sexually active, he must agree from day 1 through 6 months after the last dose of alvocidib or 90 days after the last dose of venetoclax, whichever is longer, to practice the protocol-specified protection.
- History of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.
- Prior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.
- History of previous enrollment in Studies NCT02993523 or NCT03069352.
- History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9) inhibitor.
- History of Tumor Lysis Syndrome (TLS) due to previous exposure to venetoclax.
USC / Norris Comprehensive Cancer Center
Contact: Christine Duran
UC Irvine Health / Chao Family Comprehensive Cancer Center
University of California Davis Comprehensive Cancer Center
University of Miami Miller School of Medicine-Sylvester Cancer Center
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Duke University Medical Center
University of Pittsburgh Cancer Institute (UPCI)
Trial Phase Phase I
Trial Type Treatment
- Primary ID M16-186
- Secondary IDs NCI-2018-00730, 2017-002531-42
- Clinicaltrials.gov ID NCT03441555